P24.04 Concordance of Tissue and Cell-Free DNA-Based Next-Generation Sequencing in Patients With Lung Adenocarcinoma

Abstract

Panel-based next-generation sequencing (NGS) to detect targetable somatic genetic events is guideline-recommended initial diagnostic testing in lung adenocarcinoma. Tissue biopsy has a number of limitations, including expense and biopsy-related adverse events. “Liquid biopsy” uses blood-based NGS on cell-free DNA (cfDNA). Prior investigations have demonstrated high rates of concordance at initial diagnosis. However, concordance at time of progression remains unknown.